Trial of D-Cycloserine in Schizophrenia
Launched by MASSACHUSETTS GENERAL HOSPITAL · Nov 2, 1999
Trial Information
Current as of January 15, 2025
Completed
Keywords
ClinConnect Summary
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic, and serotonergic function in serum and cerebrospinal fluid. To determine if negative symptoms and cognitive function improve over time, if these improvements meaningfully impact quality of life factors, if they correlate with markers of neuronal function, and if subpopulations can be identified according to response.
Dysfunction of glutamatergic neuronal systems has recently been implicated in...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Schizophrenia as per DSM IV criteria
- • Have been treated for at least 6 months with any conventional neuroleptic
- • Have prominent negative symptoms as defined by a total score of 40 or greater on the scale for the assessment of negative symptoms (SANS)
- Exclusion Criteria:
- • Active alcohol or drug abuse
- • Unstable Medical Illness, seizure disorder, or other serious neurological disorder
- • Pregnant or Nursing
- • Unable to complete a cognitive battery
Trial Officials
Donald Goff, MD
Principal Investigator
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials